{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:58:25Z","timestamp":1791305905631,"version":"4.3.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A plausible mechanism to explain thrombotic risk differences associated with the use of second- and third-generation oral contraceptives (OCs), particularly in carriers of factor VLeiden, is still lacking. In a double-blind trial, 51 women without and 35 women with factor VLeiden were randomized to either a second- (30 \u03bcg ethinylestradiol\/150 \u03bcg levonorgestrel) or third- (30 \u03bcg ethinylestradiol\/150 \u03bcg desogestrel) generation OC. After 2 cycles of use and a wash-out of 2 cycles, the participants continued with the corresponding progestagen-only preparation. Hemostatic variables that probe the activity of the anticoagulant protein C system were determined. Compared with levonorgestrel, desogestrel-containing OCs significantly decreased protein S and increased activated protein C (APC) resistance in both groups. OCs with desogestrel had the most pronounced effects in carriers of factor VLeiden. Progestagen-only preparations caused changes of anticoagulant parameters opposite to those of combined OCs, which in a number of cases were more pronounced with levonorgestrel. Our data show that progestagens in combined OCs counteract the thrombotic effect of the estrogen component. The higher thrombotic risk associated with third-generation OCs compared with second-generation OCs may be explained by the fact that desogestrel appeared less antithrombotic than levonorgestrel, especially in women with factor VLeiden. (Blood. 2004;103:927-933)<\/jats:p>","DOI":"10.1182\/blood-2003-04-1285","type":"journal-article","created":{"date-parts":[[2003,10,14]],"date-time":"2003-10-14T00:18:45Z","timestamp":1066090725000},"page":"927-933","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":121,"title":["Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial"],"prefix":"10.1182","volume":"103","author":[{"given":"Jeanet M.","family":"Kemmeren","sequence":"first","affiliation":[{"name":"From the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands; the Department of Neurology and the Department of Haematology, University Medical Center Utrecht, The Netherlands; the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands; and the Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale","family":"Algra","sequence":"additional","affiliation":[{"name":"From the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands; the Department of Neurology and the Department of Haematology, University Medical Center Utrecht, The Netherlands; the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands; and the Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost C. M.","family":"Meijers","sequence":"additional","affiliation":[{"name":"From the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands; the Department of Neurology and the Department of Haematology, University Medical Center Utrecht, The Netherlands; the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands; and the Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Tans","sequence":"additional","affiliation":[{"name":"From the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands; the Department of Neurology and the Department of Haematology, University Medical Center Utrecht, The Netherlands; the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands; and the Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonno N.","family":"Bouma","sequence":"additional","affiliation":[{"name":"From the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands; the Department of Neurology and the Department of Haematology, University Medical Center Utrecht, The Netherlands; the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands; and the Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Curvers","sequence":"additional","affiliation":[{"name":"From the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands; the Department of Neurology and the Department of Haematology, University Medical Center Utrecht, The Netherlands; the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands; and the Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rosing","sequence":"additional","affiliation":[{"name":"From the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands; the Department of Neurology and the Department of Haematology, University Medical Center Utrecht, The Netherlands; the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands; and the Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederick E.","family":"Grobbee","sequence":"additional","affiliation":[{"name":"From the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands; the Department of Neurology and the Department of Haematology, University Medical Center Utrecht, The Netherlands; the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands; and the Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021300055809400_REF1","doi-asserted-by":"crossref","unstructured":"Inman WH, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. BMJ. 1970;2: 203-209.","DOI":"10.1136\/bmj.2.5703.203"},{"key":"2020021300055809400_","doi-asserted-by":"crossref","unstructured":"Jespersen J, Petersen KR, Skouby SO. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol. 1990;163: 396-403.","DOI":"10.1016\/0002-9378(90)90590-4"},{"key":"2020021300055809400_REF3","doi-asserted-by":"crossref","unstructured":"Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med. 1981;305: 612-618.","DOI":"10.1056\/NEJM198109103051104"},{"key":"2020021300055809400_REF4","doi-asserted-by":"crossref","unstructured":"Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ. 1989;298: 165-168.","DOI":"10.1136\/bmj.298.6667.165"},{"key":"2020021300055809400_","doi-asserted-by":"crossref","unstructured":"La Vecchia C, Franceschi S, Decarli A, Pampallona S, Tognoni G. Risk factors for myocardial infarction in young women. Am J Epidemiol. 1987;125: 832-843.","DOI":"10.1093\/oxfordjournals.aje.a114599"},{"key":"2020021300055809400_REF6","unstructured":"Stolley PD, Strom BL, Sartwell PE. Oral contraceptives and vascular disease. Epidemiol.Rev. 1989;11: 241-243."},{"key":"2020021300055809400_REF7","doi-asserted-by":"crossref","unstructured":"World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low estrogen oral contraceptives on venous thromboembolic disease. Lancet. 1995;346: 1582-1588.","DOI":"10.1016\/S0140-6736(95)91927-9"},{"key":"2020021300055809400_REF8","doi-asserted-by":"crossref","unstructured":"Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346: 1589-1593.","DOI":"10.1016\/S0140-6736(95)91928-7"},{"key":"2020021300055809400_REF9","doi-asserted-by":"crossref","unstructured":"Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor VLeiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995;346: 1593-1596.","DOI":"10.1016\/S0140-6736(95)91929-5"},{"key":"2020021300055809400_REF10","doi-asserted-by":"crossref","unstructured":"Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study: Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ. 1996;312: 83-88.","DOI":"10.1136\/bmj.312.7023.83"},{"key":"2020021300055809400_REF11","doi-asserted-by":"crossref","unstructured":"Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor VLeiden mutation. Lancet. 1994;344: 1453-1457.","DOI":"10.1016\/S0140-6736(94)90286-0"},{"key":"2020021300055809400_REF12","doi-asserted-by":"crossref","unstructured":"Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem. 1995;270: 21158-21166.","DOI":"10.1074\/jbc.270.36.21158"},{"key":"2020021300055809400_","doi-asserted-by":"crossref","unstructured":"Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem. 1995;270: 4053-4057.","DOI":"10.1074\/jbc.270.8.4053"},{"key":"2020021300055809400_REF14","doi-asserted-by":"crossref","unstructured":"Aparicio C, Dahlback B. Molecular mechanisms of activated protein C resistance: properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. Biochem J. 1996;313(pt 2): 467-472.","DOI":"10.1042\/bj3130467"},{"key":"2020021300055809400_REF15","doi-asserted-by":"crossref","unstructured":"Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 1997;97: 233-238.","DOI":"10.1046\/j.1365-2141.1997.192707.x"},{"key":"2020021300055809400_REF16","doi-asserted-by":"crossref","unstructured":"Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study. Lancet. 1999;354: 2036-2040.","DOI":"10.1016\/S0140-6736(99)06092-4"},{"key":"2020021300055809400_REF17","doi-asserted-by":"crossref","unstructured":"Tans G, Van Hylckama Vlieg A, Thomassen MC, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol. 2003;122: 465-470.","DOI":"10.1046\/j.1365-2141.2003.04443.x"},{"key":"2020021300055809400_REF18","doi-asserted-by":"crossref","unstructured":"Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84: 15-21.","DOI":"10.1055\/s-0037-1613960"},{"key":"2020021300055809400_","doi-asserted-by":"crossref","unstructured":"Meijers JC, Middeldorp S, Tekelenburg W, et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost. 2000;84: 9-14.","DOI":"10.1055\/s-0037-1613959"},{"key":"2020021300055809400_REF20","doi-asserted-by":"crossref","unstructured":"Middeldorp S, Meijers JC, van den Ende AE, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost. 2000;84: 4-8.","DOI":"10.1055\/s-0037-1613958"},{"key":"2020021300055809400_REF21","doi-asserted-by":"crossref","unstructured":"Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med. 1984;311: 1525-1528.","DOI":"10.1056\/NEJM198412133112401"},{"key":"2020021300055809400_","doi-asserted-by":"crossref","unstructured":"Bertina RM. Molecular risk factors for thrombosis. Thromb Haemost. 1999;82: 601-609.","DOI":"10.1055\/s-0037-1615886"},{"key":"2020021300055809400_REF23","doi-asserted-by":"crossref","unstructured":"Alving BM, Comp PC. Recent advances in understanding clotting and evaluating patients with recurrent thrombosis. Am J Obstet Gynecol. 1992;167: 1184-1191.","DOI":"10.1016\/S0002-9378(12)90409-3"},{"key":"2020021300055809400_REF24","doi-asserted-by":"crossref","unstructured":"Lemus AE, Zaga V, Santillan R, et al. The oestrogenic effects of gestodene, a potent contraceptive progestin, are mediated by its A-ring reduced metabolites. J Endocrinol2000;165: 693-702.","DOI":"10.1677\/joe.0.1650693"},{"key":"2020021300055809400_REF25","doi-asserted-by":"crossref","unstructured":"Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas. 1990;12: 171-197.","DOI":"10.1016\/0378-5122(90)90003-O"},{"key":"2020021300055809400_REF26","doi-asserted-by":"crossref","unstructured":"van Wijnen M, van't Veer C, Meijers JC, Bertina RM, Bouma BN. A plasma coagulation assay for an activated protein C-independent anticoagulant activity of protein S. Thromb Haemost. 1998;80: 930-935.","DOI":"10.1055\/s-0037-1615391"},{"key":"2020021300055809400_REF27","doi-asserted-by":"crossref","unstructured":"Elisen MG, Maseland MH, Church FC, Bouma BN, Meijers JC. Role of the A+ helix in heparin binding to protein C inhibitor. Thromb Haemost. 1996;75: 760-766.","DOI":"10.1055\/s-0038-1650363"},{"key":"2020021300055809400_REF28","doi-asserted-by":"crossref","unstructured":"Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994;343: 1535-1536.","DOI":"10.1016\/S0140-6736(94)92939-4"},{"key":"2020021300055809400_REF29","doi-asserted-by":"crossref","unstructured":"Quehenberger P, Loner U, Kapiotis S, et al. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost. 1996;76: 729-734.","DOI":"10.1055\/s-0038-1650651"},{"key":"2020021300055809400_REF30","doi-asserted-by":"crossref","unstructured":"Boerger LM, Morris PC, Thurnau GR, Esmon CT, Comp PC. Oral contraceptives and gender affect protein S status. Blood. 1987;69: 692-694.","DOI":"10.1182\/blood.V69.2.692.692"},{"key":"2020021300055809400_REF31","doi-asserted-by":"crossref","unstructured":"Bloemenkamp KW, Rosendaal FR, Buller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med. 1999;159: 65-70.","DOI":"10.1001\/archinte.159.1.65"},{"key":"2020021300055809400_REF32","doi-asserted-by":"crossref","unstructured":"Tans G, Bouma BN, Bu\u0308ller HR, Rosing J. Changes of hemostatic variables during oral contraceptive use. Sem Vasc Med. 2003;3: 61-68.","DOI":"10.1055\/s-2003-38333"},{"key":"2020021300055809400_REF33","doi-asserted-by":"crossref","unstructured":"Egberg N, van Beek A, Gunnervik C, et al. Effects on the hemostatic system and liver function in relation to Implanon and Norplant: a prospective randomized clinical trial. Contraception. 1998;58: 93-98.","DOI":"10.1016\/S0010-7824(98)00070-5"},{"key":"2020021300055809400_REF34","doi-asserted-by":"crossref","unstructured":"Winkler UH, Howie H, Buhler K, Korver T, Geurts TB, Coelingh BH. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 microgram desogestrel or 30 microgram levonorgestrel. Contraception. 1998;57: 385-392.","DOI":"10.1016\/S0010-7824(98)00045-6"},{"key":"2020021300055809400_REF35","doi-asserted-by":"crossref","unstructured":"Bergink EW, Holma P, Pyorala T. Effects of oral contraceptive combinations containing levonorgestrel or desogestrel on serum proteins and androgen binding. Scand J Clin Lab Invest. 1981;41: 663-668.","DOI":"10.3109\/00365518109090512"},{"key":"2020021300055809400_REF36","doi-asserted-by":"crossref","unstructured":"McClamrock HD, Adashi EY. Pharmacokinetics of desogestrel. Am J Obstet Gynecol. 1993;168: 1021-1028.","DOI":"10.1016\/0002-9378(93)90332-D"},{"key":"2020021300055809400_REF37","doi-asserted-by":"crossref","unstructured":"Kluft C, de Maat MP, Heinemann LA, Spannagl M, Schramm W. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. Lancet. 1999;354: 832-833.","DOI":"10.1016\/S0140-6736(99)80017-8"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/3\/927\/1695219\/zh800304000927.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/3\/927\/1695219\/zh800304000927.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T02:43:52Z","timestamp":1585190632000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/3\/927\/17272\/Effect-of-second-and-thirdgeneration-oral"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,1]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-04-1285","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2,1]]}}}